Lorenzo Gianni
Rimini, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists.
Journal: Current oncology (Toronto, Ont.)
Published: November 05, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice.
Journal: Frontiers in oncology
Published: September 25, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.
Journal: Cancer treatment reviews
Published: June 21, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
Journal: BMC cancer
Published: March 03, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: January 15, 2024
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Journal: Journal for immunotherapy of cancer
Published: November 06, 2023
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 13, 2023
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 29, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Journal: Frontiers in oncology
Published: January 27, 2023
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Journal: Cancer discovery
Published: July 28, 2022
Last Updated: 09/26/2026